- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03346291
Examining Persistence in Smokers With Schizophrenia
15. januar 2019 opdateret af: Marc L. Steinberg, Ph.D., Rutgers, The State University of New Jersey
All participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks).
They will complete assessment measures commonly used in smoking cessation studies.
We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a non-randomized trial of a new psychosocial treatment for smoking cessation (for smokers with schizophrenia) that is based on cognitive behavioral therapy for smoking cessation - a commonly used approach.
Participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks).
They will complete assessment measures commonly used in smoking cessation studies.
We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
27
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rutgers Robert Wood Johnson Medical School
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 64 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Must be between 18 - 64 years old
- Must indicate commitment to quitting smoking in the next 30 days
- Must smoke at least 5 cigarettes per day for past 6-months
- Expired breath carbon monoxide (CO) > 5 to ensure daily cigarette use
- Must score < 8 (or <7 for women) on the Alcohol Use Disorders Identification Test
- Must score less than 3 on the 6-month Drug Abuse Screening Test-10
- Must provide a negative urine drug screen for cannabis, cocaine, opiates, or
- methamphetamine (Note: Participants with a positive screen for opiates may
- participate with proof of prescription for opiates.)
- Must have a diagnosis of Schizophrenia or Schizoaffective Disorder on Structured Clinical Interview
- Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks
Exclusion Criteria:
- Must not be currently receiving tobacco dependence treatment counseling
- Must not currently be taking varenicline (Chantix)
- Must not be taking bupropion (Zyban/Wellbutrin) to quit smoking
- Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days.
- Must not report unstable angina pectoris, myocardial infarction, or significant cardiac arrhythmia (including atrial fibrillation) in the past 90 days
- Must not be pregnant, breastfeeding, or planning on becoming pregnant in the next 4-months. Women who can become pregnant may be included if using effective birth control
- Must not have pending legal matters with potential to result in jail time
- Must not be planning on moving outside local area in next 3-months
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Persistence Targeted Smoking Cessation
8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
|
individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Task Persistence - Mirror Tracing
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Number of seconds persisting on a computerized mirror tracing task (Higher number of seconds = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Sustained Divided Attention Task
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Seconds persisting on Sustained Divided Attention Task (Higher number of seconds = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Breath-holding
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Number of seconds persisting on a breath-holding endurance task (Higher number of seconds = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence -Temperament and Character Inventory-Persistence Scale (TCI-P)
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on Temperament and Character Inventory-Persistence Scale (TCI-P) (Higher score = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - 2-item Task Persistence Measure
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on 2-item Task Persistence Measure (Higher score = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Distress Tolerance Scale (DTS)
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on Distress Tolerance Scale (DTS) (Higher score = greater persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Task Persistence - Thoughts About Smoking Questionnaire
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
Score on the Thoughts About Smoking Questionnaire (Higher score = less persistence)
|
Through end-of-treatment - approximately 8 weeks after baseline
|
|
Self-reported ratings of ease of understanding and helpfulness of counseling
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
|
percentage of participants who rate the intervention as "easy to understand" and "helpful"
|
Through end-of-treatment - approximately 8 weeks after baseline
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Marc L Steinberg, Ph.D., Rutgers, The State University of New Jersey
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. januar 2017
Primær færdiggørelse (Faktiske)
13. juni 2018
Studieafslutning (Faktiske)
13. juni 2018
Datoer for studieregistrering
Først indsendt
3. november 2017
Først indsendt, der opfyldte QC-kriterier
14. november 2017
Først opslået (Faktiske)
17. november 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
17. januar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
15. januar 2019
Sidst verificeret
1. januar 2019
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 20150001885
- R21DA041163-01 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Ingen
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med counseling
-
Northwestern UniversityGeorgetown UniversityAfsluttetKroniske nyresygdomme | Genetisk dispositionForenede Stater
-
University of California, BerkeleyNational Institute of Mental Health (NIMH); Ministry of Health, Tanzania; Management and Development for Health og andre samarbejdspartnereAktiv, ikke rekrutterende
-
Texas Christian UniversityAfsluttetMapping Enhanced Counseling (MEC) | Active Linkage (AL)Forenede Stater
-
Texas Christian UniversityAktiv, ikke rekrutterendeKortlægningsmetoder til forberedelse af implementeringsoverførsel | Behandlingsparathed og introduktionsprogramForenede Stater
-
University of TartuState University of New York - Downstate Medical Center; Tibotec Pharmaceutical...AfsluttetErhvervet immundefektsyndrom | Medicinadhærens | Akut HIV-infektionEstland
-
Makerere UniversityMinistry of Health, Uganda; Rakai Health Sciences ProjectAktiv, ikke rekrutterende
-
University of California, San DiegoKenya Ministry of Health; Population Council KenyaAfsluttet
-
Yale UniversityNational Institute on Drug Abuse (NIDA)AfsluttetHIV-infektioner | OpiatafhængighedKina, Forenede Stater
-
University of California, Los AngelesBrown UniversityAfsluttetForebyggelseForenede Stater
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los Angeles County Department of Public Health og andre samarbejdspartnereAfsluttetHIV-forebyggelseForenede Stater